UPCC 20924 A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product

Investigation of Long-Term Safety of CAR T Cell Therapy

Enrolling By Invitation
18 years or above
All
Phase N/A
60 participants needed
1 Location

Brief description of study

The primary purpose of this study is to monitor potential long-term risks associated with the administration of SynKIR CAR T cell products.

Detailed description of study

This is a study for the Long Term Follow Up for all participants treated with Verismo Therapeutics' SynKIR CAR T cell products in accordance with regulatory guidance. The primary objective of this study is to monitor the long-term safety of SynKIR CAR T cell products.

No investigational product will be administered in this LTFU study. Eligible participants must have received at least 1 infusion of a SynKIR CAR T cell product under a Verismo Therapeutics parent protocol. Participants will be invited to enroll into this LTFU study after either early discontinuation from or completion of the parent protocol.

In accordance with regulatory guidelines, this study will follow participants for a period of 15 years following infusion of Verismo Therapeutics' SynKIR CAR T cell product, to monitor for delayed adverse events (AEs), detection of replication competent lentivirus (RCL), and to assess long-term efficacy and persistence of gene-modified T cells.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cancer
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. All adult participants who have received any amount of SynKIR CAR T cell product in a study sponsored by Verismo Therapeutics.
  2. Participant is willing and able to comply with the study requirements.

Exclusion Criteria:

There are no specific exclusion criteria.

The purpose of this study is to investigate the long-term safety of a type of treatment called CAR T cell therapy. This study focuses on monitoring the long-term risks associated with this therapy, such as delayed adverse events and the persistence of modified T cells in the body.

Participants in this study will not receive any investigational medication or vaccine. Instead, the study will follow individuals who have previously received CAR T cell therapy to observe their health over time. This involves monitoring for any long-term side effects and assessing the continued presence and effectiveness of the modified T cells.

  • Who can participate: Adults who have previously received SynKIR CAR T cell therapy in a study by Verismo Therapeutics and are willing to comply with study requirements can participate.
  • Study details: Participants will not receive any investigational medication or vaccine. The study will involve regular health monitoring to observe long-term effects of the CAR T cell therapy.
  • Study timelines: The study will last 15 years.
Updated on 10 Feb 2026. Study ID: 24-2141
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator